Does the media favor ELVN or CYRX?

In the previous week, Enliven Therapeutics had 4 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Enliven Therapeutics and 1 mentions for CryoPort. Enliven Therapeutics' average media sentiment score of 0.93 beat CryoPort's score of 0.42 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MOR or CYRX?

CryoPort has a consensus target price of $15.11, suggesting a potential downside of 2.45%. Given CryoPort's stronger consensus rating and higher possible upside, analysts plainly believe CryoPort is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CryoPort 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has preferable valuation & earnings, MOR or CYRX?

CryoPort has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A CryoPort $182.94M 4.27 $78.30M $1.35 11.47

Is MOR or CYRX more profitable?

CryoPort has a net margin of 41.57% compared to MorphoSys' net margin of -226.79%. CryoPort's return on equity of -7.92% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% CryoPort 41.57% -7.92% -4.79%

Does the media prefer MOR or CYRX?

In the previous week, MorphoSys and MorphoSys both had 1 articles in the media. CryoPort's average media sentiment score of 0.42 beat MorphoSys' score of -0.71 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TARS or CYRX?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than CryoPort. MarketBeat recorded 3 mentions for Tarsus Pharmaceuticals and 1 mentions for CryoPort. CryoPort's average media sentiment score of 0.42 beat Tarsus Pharmaceuticals' score of 0.14 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RARE or CYRX?

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for Ultragenyx Pharmaceutical and 1 mentions for CryoPort. Ultragenyx Pharmaceutical's average media sentiment score of 1.35 beat CryoPort's score of 0.42 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CYRX or KLRA?

In the previous week, Kailera Therapeutics had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for Kailera Therapeutics and 1 mentions for CryoPort. CryoPort's average media sentiment score of 0.42 beat Kailera Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CryoPort (CYRX) Competitors

$15.49 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$15.50 +0.01 (+0.06%)

As of 07/2/2026 07:50 PM Eastern

Compare

CYRX vs. ELVN, MOR, TARS, RARE, and KLRA

Should you buy CryoPort stock or one of its competitors? MarketBeat compares CryoPort with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CryoPort include Enliven Therapeutics (ELVN), MorphoSys (MOR), Tarsus Pharmaceuticals (TARS), Ultragenyx Pharmaceutical (RARE), and Kailera Therapeutics (KLRA). These companies are all part of the "pharmaceutical products" industry.

How does CryoPort compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Enliven Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

CryoPort has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47

CryoPort has a net margin of 41.57% compared to Enliven Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
CryoPort	41.57%	-7.92%	-4.79%

In the previous week, Enliven Therapeutics had 4 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Enliven Therapeutics and 1 mentions for CryoPort. Enliven Therapeutics' average media sentiment score of 0.93 beat CryoPort's score of 0.42 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics currently has a consensus price target of $67.83, suggesting a potential upside of 36.16%. CryoPort has a consensus price target of $15.11, suggesting a potential downside of 2.45%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

CryoPort beats Enliven Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CryoPort compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

CryoPort has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

CryoPort has a net margin of 41.57% compared to MorphoSys' net margin of -226.79%. CryoPort's return on equity of -7.92% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
CryoPort	41.57%	-7.92%	-4.79%

CryoPort has a consensus target price of $15.11, suggesting a potential downside of 2.45%. Given CryoPort's stronger consensus rating and higher possible upside, analysts plainly believe CryoPort is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, MorphoSys and MorphoSys both had 1 articles in the media. CryoPort's average media sentiment score of 0.42 beat MorphoSys' score of -0.71 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 10.0% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

CryoPort beats MorphoSys on 13 of the 15 factors compared between the two stocks.

How does CryoPort compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

CryoPort has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.24	-$66.42M	-$1.14	N/A
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47

Tarsus Pharmaceuticals currently has a consensus price target of $90.67, suggesting a potential upside of 38.55%. CryoPort has a consensus price target of $15.11, suggesting a potential downside of 2.45%. Given Tarsus Pharmaceuticals' higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 10.0% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CryoPort has a net margin of 41.57% compared to Tarsus Pharmaceuticals' net margin of -9.02%. CryoPort's return on equity of -7.92% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
CryoPort	41.57%	-7.92%	-4.79%

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than CryoPort. MarketBeat recorded 3 mentions for Tarsus Pharmaceuticals and 1 mentions for CryoPort. CryoPort's average media sentiment score of 0.42 beat Tarsus Pharmaceuticals' score of 0.14 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Summary

CryoPort beats Tarsus Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does CryoPort compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for Ultragenyx Pharmaceutical and 1 mentions for CryoPort. Ultragenyx Pharmaceutical's average media sentiment score of 1.35 beat CryoPort's score of 0.42 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 10.0% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical currently has a consensus price target of $59.56, indicating a potential upside of 77.96%. CryoPort has a consensus price target of $15.11, indicating a potential downside of 2.45%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

CryoPort has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.90	-$575M	-$6.11	N/A
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47

CryoPort has a net margin of 41.57% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. CryoPort's return on equity of -7.92% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
CryoPort	41.57%	-7.92%	-4.79%

Summary

Ultragenyx Pharmaceutical beats CryoPort on 9 of the 17 factors compared between the two stocks.

How does CryoPort compare to Kailera Therapeutics?

CryoPort (NASDAQ:CYRX) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Kailera Therapeutics had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for Kailera Therapeutics and 1 mentions for CryoPort. CryoPort's average media sentiment score of 0.42 beat Kailera Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of CryoPort shares are held by institutional investors. 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CryoPort has higher revenue and earnings than Kailera Therapeutics. Kailera Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A

CryoPort has a net margin of 41.57% compared to Kailera Therapeutics' net margin of 0.00%. Kailera Therapeutics' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Kailera Therapeutics	N/A	N/A	N/A

CryoPort presently has a consensus target price of $15.11, indicating a potential downside of 2.45%. Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 94.41%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

CryoPort beats Kailera Therapeutics on 8 of the 14 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYRX vs. The Competition

Export

Metric	CryoPort	TRANS Industry	Transportation Sector	NASDAQ Exchange
Market Cap	$780.73M	$7.46B	$8.75B	$12.47B
Dividend Yield	N/A	2.44%	974.11%	6.51%
P/E Ratio	11.47	30.50	24.88	24.70
Price / Sales	4.27	2.44	4.67	99.69
Price / Cash	N/A	9.99	8.32	57.09
Price / Book	1.69	2.59	2.26	6.46
Net Income	$78.30M	$243.42M	$531.96M	$337.01M
7 Day Performance	-3.18%	0.53%	0.02%	1.69%
1 Month Performance	-1.34%	-0.94%	-1.26%	3.81%
1 Year Performance	102.75%	-8.12%	24.69%	23.90%

CryoPort Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYRX CryoPort	3.4036 of 5 stars	$15.49 flat	$15.11 -2.4%	+102.7%	$780.73M	$182.94M	11.47	1,186
ELVN Enliven Therapeutics	3.4153 of 5 stars	$47.77 -1.7%	$63.40 +32.7%	+141.0%	$2.96B	N/A	N/A	50	Analyst Forecast Gap Down
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730	News Coverage
TARS Tarsus Pharmaceuticals	2.9203 of 5 stars	$67.11 +1.4%	$90.67 +35.1%	+59.3%	$2.85B	$451.36M	N/A	50	News Coverage
RARE Ultragenyx Pharmaceutical	3.8381 of 5 stars	$29.11 +1.2%	$59.56 +104.6%	-14.6%	$2.83B	$673M	N/A	1,371	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CryoPort (CYRX) Competitors

CYRX vs. ELVN, MOR, TARS, RARE, and KLRA

How does CryoPort compare to Enliven Therapeutics?

Summary

How does CryoPort compare to MorphoSys?

Summary

How does CryoPort compare to Tarsus Pharmaceuticals?

Summary

How does CryoPort compare to Ultragenyx Pharmaceutical?

Summary

How does CryoPort compare to Kailera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CryoPort (CYRX) Competitors

CYRX vs. ELVN, MOR, TARS, RARE, and KLRA

How does CryoPort compare to Enliven Therapeutics?

Do institutionals and insiders have more ownership in ELVN or CYRX?

Which has more volatility & risk, ELVN or CYRX?

Which has preferable earnings and valuation, ELVN or CYRX?

Is ELVN or CYRX more profitable?

Does the media favor ELVN or CYRX?

Do analysts recommend ELVN or CYRX?

Summary

How does CryoPort compare to MorphoSys?

Which has preferable valuation & earnings, MOR or CYRX?

Which has more risk & volatility, MOR or CYRX?

Is MOR or CYRX more profitable?

Do analysts rate MOR or CYRX?

Does the media prefer MOR or CYRX?

Do institutionals & insiders have more ownership in MOR or CYRX?

Summary

How does CryoPort compare to Tarsus Pharmaceuticals?

Which has stronger earnings and valuation, TARS or CYRX?

Do analysts rate TARS or CYRX?

Do institutionals and insiders have more ownership in TARS or CYRX?

Is TARS or CYRX more profitable?

Does the media prefer TARS or CYRX?

Which has more risk and volatility, TARS or CYRX?

Summary

How does CryoPort compare to Ultragenyx Pharmaceutical?

Does the media prefer RARE or CYRX?

Which has more volatility & risk, RARE or CYRX?

Do insiders and institutionals have more ownership in RARE or CYRX?

Do analysts prefer RARE or CYRX?

Which has stronger valuation & earnings, RARE or CYRX?

Is RARE or CYRX more profitable?

Summary

How does CryoPort compare to Kailera Therapeutics?

Does the media favor CYRX or KLRA?

Do insiders & institutionals believe in CYRX or KLRA?

Which has better valuation and earnings, CYRX or KLRA?

Is CYRX or KLRA more profitable?

Do analysts rate CYRX or KLRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools